Financial Support.

CLL Society links you with various sources of financial support including the relevant pharmaceutical companies, non-profits, and government sources to help with expenses.

4 Steps to Take Now

Step One

Eget mauris pharetra et ultrices neque. Orci a scelerisque purus semper eget duis at tellus at. Vel facilisis volutpat est velit egestas dui id. Ut ornare lectus sit amet est placerat in. Suspendisse potenti nullam ac tortor vitae. Commodo odio aenean sed adipiscing diam.

Step Two

Eget mauris pharetra et ultrices neque. Orci a scelerisque purus semper eget duis at tellus at. Vel facilisis volutpat est velit egestas dui id. Ut ornare lectus sit amet est placerat in. Suspendisse potenti nullam ac tortor vitae. Commodo odio aenean sed adipiscing diam.

Step Three

Eget mauris pharetra et ultrices neque. Orci a scelerisque purus semper eget duis at tellus at. Vel facilisis volutpat est velit egestas dui id. Ut ornare lectus sit amet est placerat in. Suspendisse potenti nullam ac tortor vitae. Commodo odio aenean sed adipiscing diam.

Step Four

Eget mauris pharetra et ultrices neque. Orci a scelerisque purus semper eget duis at tellus at. Vel facilisis volutpat est velit egestas dui id. Ut ornare lectus sit amet est placerat in. Suspendisse potenti nullam ac tortor vitae. Commodo odio aenean sed adipiscing diam.

ARTICLES ON FINANCIAL SUPPORT

SUSAN LANG PRE-CAR-T CELL THERAPY TRAVEL ASSISTANCE PROGRAM  More good news. The Leukemia and Lymphoma Society (LLS) is offering financial help with travel and lodging expenses up to $2,500 for those who qualify by having an income < 500% of the U.S. federal poverty guidelines . It pays for expenses
RECENT NEWS

Update to the FDA Fact Sheet for Healthcare Providers: Emergency Use Authorization for Evusheld

On October 3, 2022, the FDA updated the guidance offered to healthcare providers concerning Evusheld (the cocktail of two COVID-19 monoclonal antibodies, tixagevimab, and cilgavimab). Evusheld which is currently the only authorized  Pre-Exposure Prophylaxis (PrEP) against COVID-19 for the immunocompromised, including those with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), in whom protection provided by the COVID-19 vaccine is unpredictable and less robust.

Read More »
NEWS ARCHIVES